



## Current Agreements

### Dealdoc

#### Collaboration agreement for Generx and Excellagen

Cardium Therapeutics  
Taxus Pharmaceuticals

Mar 03 2014

## Collaboration agreement for Generx and Excellagen

<b>Companies:</b>	<a href="#">Cardium Therapeutics</a> <a href="#">Taxus Pharmaceuticals</a>
<b>Announcement date:</b>	Mar 03 2014
<b>Deal value, US\$m:</b>	5 : sum of equity funding

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

### Details

<b>Announcement date:</b>	Mar 03 2014
<b>Industry sectors:</b>	Biotech Pharmaceutical
<b>Brand name:</b>	Generx, Excellagen
<b>Asset type:</b>	Compound Product
<b>Therapy areas:</b>	Cardiovascular
<b>Technology types:</b>	Regenerative medicine Collaborative R&D
<b>Deal components:</b>	Equity purchase Preclinical
<b>Stages of development:</b>	Phase I Phase II Phase III

### Financials

<b>Deal value, US\$m:</b>	5 : sum of equity funding
<b>Equity, US\$m:</b>	5 : purchased at a premium above the then-prevailing average market price of Cardium common stock

### Termsheet

Cardium Therapeutics has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx product candidate and Excellagen, FDA-cleared advanced wound care product.

The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration.

The strategic collaboration is designed to support the commercial development of Generx and Excellagen by Cardium, and also provide new opportunities to explore the commercialization of these products for the emerging and rapidly growing advanced healthcare market in the People's Republic China, and Taxus oncology-focused product opportunities for the U.S. market.

The deal includes funding in the form of direct investments in Cardium of up to \$5.0 million to support the commercialization of Cardium's products.

Stock acquired by Taxus in connection with the strategic alliance will be purchased at a premium above the then-prevailing average market price of Cardium common stock.

Cardium obtained an initial tranche of funding pursuant to the agreement by selling approximately 714,000 shares of common stock at \$0.70 per share.

Future tranches of up to \$4.5 million would be sold at a 10% premium to the then-prevailing market price, based on a thirty day trailing average.

The stock acquired is unregistered common stock and no warrants will be issued.

## Press Release

### Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development of Advanced Regenerative Therapeutics

SAN DIEGO, CA – March 3, 2014 – Cardium Therapeutics Inc. (Trading Symbol: CRXM) reported that it has entered into a strategic collaboration and funding arrangement with Shanxi Taxus Pharmaceuticals Co., Ltd., which is affiliated with Shenzhen Forntsea Taxus Industry Capital Management, to support the worldwide clinical and commercial development of Cardium's advanced regenerative medicine therapeutics products, including Generx® product candidate and Excellagen®, FDA-cleared advanced wound care product. The Company's name will be changed to Taxus Cardium Pharmaceuticals Group in connection with the strategic collaboration. The strategic collaboration is designed to support the commercial development of Generx and Excellagen by Cardium, and also provide new opportunities to explore the commercialization of these products for the emerging and rapidly growing advanced healthcare market in the People's Republic of China, and Taxus oncology-focused product opportunities for the U.S. market. The deal includes funding in the form of direct investments in Cardium of up to \$5.0 million to support the commercialization of Cardium's products. Stock acquired by Taxus in connection with the strategic alliance will be purchased at a premium above the then-prevailing average market price of Cardium common stock. Cardium obtained an initial tranche of funding pursuant to the agreement by selling approximately 714,000 shares of common stock at \$0.70 per share. Future tranches of up to \$4.5 million would be sold at a 10% premium to the then-prevailing market price, based on a thirty day trailing average. The stock acquired is unregistered common stock and no warrants will be issued. In January 2014, Cardium reported encouraging initial clinical pilot study findings from its ASPIRE international Phase 3 registration clinical study, which is designed to confirm the continued safety and effectiveness from four previously completed clinical studies of Generx as an interventional cardiology angiogenic gene therapy for the potential treatment of cardiac microvascular insufficiency, a condition that leads to myocardial ischemia due to advanced coronary artery disease <http://www.cardiumthx.com/timeline/>. Cardium also recently reported on advances in the commercial development of Excellagen as an advanced wound care therapy. Excellagen is an FDA-cleared, acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics. On January 1, 2014, Excellagen received a unique Q code product reimbursement designation as a "skin substitute" for the treatment of diabetic foot ulcers and a broad array of other wounds product by the U.S. Centers for Medicare and Medicaid Services (CMS). Cardium also reported on new preclinical studies that Excellagen facilitates the use of allogeneic stem cells for diabetic wound healing and autologous tissue scaffolding. For more information about Cardium's business strategy, product development focus and key objectives and activities for 2014, please visit <http://www.cardiumthx.com/CRXM-Presentation-2014.pdf> In connection with the strategic collaboration, Taxus will also cooperate with Cardium to develop opportunities for the regulatory approval and commercialization of Generx and Excellagen in China, which has a rapidly growing market and needs for advanced healthcare including products for the treatment of heart disease and advanced wound care. Cardium will also have the opportunity to work with Taxus on the development of new and innovative product opportunities for Taxol (Paclitaxel) based products in the United States. Mr. Jiayue Zhang, who is the Chairman of Taxus, and an additional individual with U.S. corporate and financial experience, have agreed to join Cardium's Board of Directors. Cardium will change its name to Taxus Cardium Pharmaceuticals Group. The stock trading symbol will remain unchanged. "We are very pleased to enter into a strategic collaboration with a developer of innovative new therapies for the potential treatment of major medical indications, including cardiovascular disease and advanced wound care which has major applications for use in patients with diabetes, a condition that is already large and rapidly growing, in the U.S., China and throughout the world," stated Mr. Jiayue Zhang, Chairman of Shanxi Taxus Pharmaceuticals. "We also look forward to developing pathways through which Taxus products for use in the treatment of cancer and other conditions can be introduced into U.S. markets through this strategic alliance," he further reported. "Cardium is the leader in the field of cardiac gene therapy. Since our acquisition of Generx from Schering AG, Cardium now has the world's largest clinical and regulatory dossier for a cardiac gene therapy product candidate, which now includes four completed randomized and controlled clinical studies, with study data published in peer-reviewed journals that involves over 750 patients with advanced coronary artery disease at more than 100 medical centers in the United States, South America, Canada, Western Europe and the Russian Federation," noted Christopher Reinhard, Cardium's co-founder and chief executive officer. "With encouraging initial findings from our current ASPIRE clinical study, our Generx program is now a central focus for the Company and we are developing plans to accelerate the Generx product development program. Through this effort we seek to be in a position to provide an interim data analysis in mid-2014," he further reported. About Cardium Cardium is a development stage advanced regenerative therapeutics company that is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics including (1) Generx®, an interventional cardiology, angiogenic gene therapy product candidate designed for the treatment of patients with cardiac microvascular insufficiency with myocardial ischemia due to advanced coronary artery disease <https://www.youtube.com/watch?v=pjUndFhKjM&feature=email>, and (2) Excellagen®, an FDA-cleared acellular biological skin substitute designed as a professional-use advanced wound care product for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers, which also has multiple additional potential tissue regeneration applications based on stem cells and other biologics (<http://www.excellagen.com/>). For more information about Cardium's product development activities please visit <http://www.cardiumthx.com/CRXM-Presentation-2014.pdf> About Shanxi Taxus Pharmaceuticals Shanxi Taxus Pharmaceuticals Co., Ltd. (Shanxi Taxus) is a pharmaceutical company engaged in research and development focused on the natural resource cultivation and

manufacture of paclitaxel, an anti-cancer medication. Headquartered in Jinzhong City, Shanxi Province, China, Shanxi Taxus has several lines of business including natural resource management, retail pharmacy and healthcare product manufacturing. Principals of Shanxi Taxus have interests in banking and finance that includes a private equity arm. Shanxi Taxus initiatives are aimed at securing strategic partners with access to the U.S. and other markets whereby both parties can expand their markets and gain access to capital and technical expertise to develop new and innovative medical products.

### **Filing Data**

*Not available.*

### **Contract**

*Not available.*